Status:
COMPLETED
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Tumors
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically diagnosed solid tumor in whom no standard therapy is available or the malignancy is refractory to standard therapy
Exclusion
- Patients with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks
- Any uncontrolled concomitant illness
- Pregnant or breast-feeding
- Serious drug or food allergy
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00373490
Start Date
July 1 2006
End Date
October 1 2007
Last Update
August 27 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.